Abstract
Platinum (II) drugs, including cisplatin, carboplatin, and oxaliplatin, have achieved significant clinical success in cancer treatment. However, their clinical application has been greatly hindered by various adverse factors, such as non-specific activation and drug resistance. Compared with Pt(II) drugs, the axial ligands within Pt(IV) compounds can improve the pharmacokinetic properties, selectivity, and biological activity, implementing alternative cytotoxic mechanisms beyond DNA cross-linking and partially overcoming drug resistance. The controlled conversion of Pt(IV) prodrugs into Pt(II) agents at the tumor site has been extensively explored internationally. In this review, Pt(IV) prodrug modification strategies are first summarized, and the development of the predominant external and internal photosensitizers is listed. Finally, three representative photoreduction mechanisms and strategies for developing corresponding Pt(IV) prodrugs are discussed. This work provides constructive instruction for the subsequent molecular design of Pt(IV) prodrugs.
[1]
Ji, G. Biopolymer immune implants’ sequential activation of innate and adaptive immunity for colorectal cancer postoperative immunotherapy. Adv. Mater., 2021, 33(3), 2004559.
[2]
Bulfoni, M. In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis. Breast Cancer Res., 2016, 18(1), 1-15.
[3]
Sun, Y.F. Circulating stem cell–like epithelial cell adhesion molecule–positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology, 2013, 57(4), 1458-1468.
[4]
Li, X.; Lee, S.; Yoon, J. Supramolecular photosensitizers rejuvenate photodynamic therapy. Chem. Soc. Rev., 2018, 47(4), 1174-1188.
[5]
Luby, B.M.; Walsh, C.D.; Zheng, G. Advanced photosensitizer activation strategies for smarter photodynamic therapy beacons. Angew. Chem. Int. Ed., 2019, 58(9), 2558-2569.
[6]
Celli, J.P. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem. Rev., 2010, 110(5), 2795-2838.
[7]
Hu, J-J.; Lei, Q.; Zhang, X-Z. Recent advances in photonanomedicines for enhanced cancer photodynamic therapy. Prog. Mater. Sci., 2020, 114, 100685.
[8]
Pham, T.C. Recent strategies to develop innovative photosensitizers for enhanced photodynamic therapy. Chem. Rev., 2021, 121(21), 13454-13619.
[9]
Rautio, J. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov., 2008, 7(3), 255-270.
[10]
Rautio, J. The expanding role of prodrugs in contemporary drug design and development. Nat. Rev. Drug Discov., 2018, 17(8), 559-587.
[12]
Luo, D. Chemophototherapy: an emerging treatment option for solid tumors. Adv. Sci., 2017, 4(1), 1600106.
[13]
Cao, Z. ROS-sensitive polymeric nanocarriers with red light-activated size shrinkage for remotely controlled drug release. Chem. Mater., 2018, 30(2), 517-525.
[14]
Yang, X. Photo-triggered self-destructive ROS-responsive nanoparticles of high paclitaxel/chlorin e6 co-loading capacity for synergetic chemo-photodynamic therapy. J. Control. Release, 2020, 323, 333-349.
[15]
Rosenberg, B.; VanCamp, L.; Trosko, J.E.; Mansour, V.H. Platinum compounds: A new class of potent antitumour agents. Nature, 1969, 222(5191), 385-386.
[16]
Wheate, N.J. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans., 2010, 39(35), 8113-8127.
[17]
Wong, E.; Giandomenico, C.M. ChemInform abstract: Current status of platinum-based antitumor drugs. Chem. Rev., 1999, 99(9)), 2451-2466.
[18]
Kelland, L.; Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer, 2007, 7(8), 573-584.
[19]
Tixier, F. Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed/refractory lymphoma patients. Hematol. Oncol., 2017, 35(4), 584-590.
[20]
Langer, T. Understanding platinum-induced ototoxicity. Trends Pharmacol. Sci., 2013, 34(8), 458-469.
[21]
Park, S.B. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain, 2009, 132(10), 2712-2723.
[22]
Aguilar, A. OCT2 demethylation cracks open oxaliplatin resistance. Nat. Rev. Nephrol., 2016, 12(10), 581-581.
[23]
Lasorsa, A. Mechanistic and structural basis for inhibition of copper trafficking by platinum anticancer drugs. J. Am. Chem. Soc., 2019, 141(30), 12109-12120.
[24]
Fuertes, M.A.; Alonso, C.; Pérez, J.M. Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem. Rev., 2003, 103(3), 645-662.
[25]
Johnstone, T.C.; Suntharalingam, K.; Lippard, S.J. The next generation of platinum drugs: targeted Pt (II) agents, nanoparticle delivery, and Pt (IV) prodrugs. Chem. Rev., 2016, 116(5), 3436-3486.
[26]
Hall, M.D. Basis for design and development of platinum (IV) anticancer complexes. J. Med. Chem., 2007, 50(15), 3403-3411.
[27]
Pendyala, L. Studies on the human metabolism of iproplatin. Cancer Chemother. Pharmacol., 1989, 25, 10-14.
[28]
Awuah, S.G. A Pt (IV) pro-drug preferentially targets indoleamine-2, 3-dioxygenase, providing enhanced ovarian cancer immuno-chemotherapy. J. Am. Chem. Soc., 2015, 137(47), 14854-14857.
[29]
Gandioso, A. An integrin-targeted photoactivatable Pt (IV) complex as a selective anticancer pro-drug: synthesis and photoactivation studies. Chem. Commun., 2015, 51(44), 9169-9172.
[30]
Qi, D. A GSH-depleted platinum(IV) prodrug triggers ferroptotic cell death in breast cancer. Chin. Chem. Lett., 2022, 33(10), 4595-4599.
[31]
Dixon, S.J. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell, 2012, 149(5), 1060-1072.
[32]
Ma, L. A cancer cell-selective and low-toxic bifunctional heterodinuclear Pt(IV)–Ru(II) aAnticancer prodrug. Inorg. Chem., 2018, 57(5), 2917-2924.
[33]
Mao, X. Synthesis and validation of a bioinspired catechol-functionalized Pt(IV) prodrug for preclinical intranasal glioblastoma treatment. Cancers (Basel), 2022, 14(2), 410.
[34]
Butler, J.S.; Sadler, P.J. Targeted delivery of platinum-based anticancer complexes. Curr. Opin. Chem. Biol., 2013, 17(2), 175-188.
[35]
Hall, M.D.; Hambley, T.W. Platinum (IV) antitumour compounds: their bioinorganic chemistry. Coord. Chem. Rev., 2002, 232(1-2), 49-67.
[36]
Graf, N.; Lippard, S.J. Redox activation of metal-based prodrugs as a strategy for drug delivery. Adv. Drug Deliv. Rev., 2012, 64(11), 993-1004.
[37]
Chen, C.K. Influence of equatorial and axial carboxylato ligands on the kinetic inertness of platinum (IV) complexes in the presence of ascorbate and cysteine and within DLD-1 cancer cells. J. Med. Chem., 2013, 56(21), 8757-8764.
[38]
Kastner, A. A dogma in doubt: hydrolysis of equatorial ligands of PtIV complexes under physiological conditions. Angew. Chem. Int. Ed., 2019, 58(22), 7464-7469.
[39]
Spector, D. Pt (IV) prodrugs with NSAIDs as axial ligands. Int. J. Mol. Sci., 2021, 22(8), 3817.
[40]
Imran, M. Photoactivated platinum-based anticancer drugs. Coord. Chem. Rev., 2018, 376, 405-429.
[41]
Kratochwil, N.A.; Bednarski, P.J. Relationships between Reduction Properties and Cancer Cell Growth Inhibitory Activities of cis-Dichloro- and cis-Diiodo-Pt(IV)-ethylenediamines. Arch. Pharm. (Weinheim), 1999, 332(8), 279-285.
[42]
Neumann, C.; Grünert, R.; Bednarski, P.J. Nicotinamide adenine dinucleotide phosphate-regenerating system coupled to a glutathione-reductase microtiter method for determination of total glutathione concentrations in adherent growing cancer cell lines. Anal. Biochem., 2003, 320(2), 170-178.
[43]
Kratochwil, N.A.; Bednarski, P.J. Effect of thiols exported by cancer cells on the stability and growth-inhibitory activity of Pt (IV) complexes. J. Cancer Res. Clin. Oncol., 1999, 125, 690-696.
[44]
Kratochwil, N.A. Electron-transfer-driven trans-ligand labilization: a novel activation mechanism for Pt (IV) anticancer complexes. J. Am. Chem. Soc., 1998, 120(32), 8253-8254.
[45]
Lemma, K. Kinetics and mechanism for reduction of anticancer-active tetrachloroam (m) ine platinum (IV) compounds by glutathione. J. Biol. Inorg. Chem., 2000, 5, 300-306.
[46]
Bednarski, P.J. Light-activated destruction of cancer cell nuclei by platinum diazide complexes. Chem. Biol., 2006, 13(1), 61-67.
[49]
Xiao, H. Maximizing synergistic activity when combining RNAi and platinum-based anticancer agents. J. Am. Chem. Soc., 2017, 139(8), 3033-3044.
[50]
Spector, D.V. Pt(IV) Prodrugs with Non-Steroidal Anti-inflammatory Drugs in the Axial Position. J. Med. Chem., 2022, 65(12), 8227-8244.
[51]
Spector, D.V. Electrochemical Detection of a Novel Pt(IV) Prodrug with the Metronidazole Axial Ligand in the Hypoxic Area. Inorg. Chem., 2022, 61(37), 14705-14717.
[52]
Yuan, Y. Pt(IV) Prodrug as a Potential Antitumor Agent with APE1 Inhibitory Activity. J. Med. Chem., 2022, 65(22), 15344-15357.
[53]
Tsipis, A.C.; Karapetsas, I.N. Prediction of 195Pt NMR of photoactivable diazido-and azine-Pt (IV) anticancer agents by DFT computational protocols. Magn. Reson. Chem., 2017, 55(2), 145-153.
[54]
Wei, D. Photo-Reduction with NIR Light of Nucleus-Targeting PtIV Nanoparticles for Combined Tumor-Targeted Chemotherapy and Photodynamic Immunotherapy. Angew. Chem. Int. Ed., 2022, 61(20), e202201486.
[55]
Imberti, C. Facile protein conjugation of platinum for light-activated cytotoxic payload release. Chem. Commun., 2021, 57(62), 7645-7648.
[56]
Min, Y. Near-infrared light-mediated photoactivation of a platinum antitumor prodrug and simultaneous cellular apoptosis imaging by upconversion-luminescent nanoparticles. Angew. Chem. Int. Ed., 2014, 53(4), 1012-1016.
[57]
Tang, D. NIR-II Light Accelerated Prodrug Reduction of Pt (IV)-Incorporating Pseudo-Semiconducting Polymers for Robust Degradation and Maximized Photothermal/Chemo-immunotherapy. Adv. Mater., 2023, 35(28), 2300048.
[58]
Li, Y. A red-light activatable and mitochondrion-targeting Pt IV complex to overcome drug resistance. Chem. Commun., 2022, 58(60), 8404-8407.
[59]
Gandioso, A. Unexpected photoactivation pathways in a folate-receptor-targeted trans-diazido Pt (IV) anticancer pro-drug. Dalton Trans., 2020, 49(34), 11828-11834.
[60]
Krasnovskaya, O.O. Photoinduced Reduction of Novel Dual-Action Riboplatin Pt(IV) Prodrug. ACS Appl. Mater. Interfaces, 2023, 15(10), 12882-12894.
[61]
Ma, Z. Differentiated oxidation modes of guanine between CpG and 5m CpG by a photoactivatable Pt (iv) anticancer prodrug. Dalton Trans., 2023, 52(9), 2786-2798.
[62]
Shi, H. DNA-Intercalative Platinum Anticancer Complexes Photoactivated by Visible Light. Chemistry, 2021, 27(41), 10711-10716.
[63]
Romero-Canelón, I.; Mos, M.; Sadler, P.J. Enhancement of selectivity of an organometallic anticancer agent by redox modulation. J. Med. Chem., 2015, 58(19), 7874-7880.
[64]
Weiss, J.T. Extracellular palladium-catalysed dealkylation of 5-fluoro-1-propargyl-uracil as a bioorthogonally activated prodrug approach. Nat. Commun., 2014, 5(1), 3277.
[65]
Völker, T. Progress towards bioorthogonal catalysis with organometallic compounds. Angew. Chem. Int. Ed., 2014, 53(39), 10536-10540.
[66]
Massey, V. The chemical and biological versatility of riboflavin. Biochem. Soc. Trans., 2000, 28(4), 283-296.
[67]
Srivastava, V. Synthetic applications of flavin photocatalysis: a review. RSC Advances, 2021, 11(23), 14251-14259.
[68]
Gurruchaga-Pereda, J. Flavin Bioorthogonal Photocatalysis Toward Platinum Substrates. ACS Catal., 2020, 10(1), 187-196.
[69]
Sánchez-Camacho, J. Flavin-Conjugated Pt(IV) Anticancer Agents. Inorg. Chem., 2023, 62(14), 5644-5651.
[70]
Canil, G. Synthesis, Characterization and Photoactivation Studies on the Novel Pt(IV)-Based [Pt(OCOCH3)3(phterpy)] Complex. Int. J. Mol. Sci., 2023, 24(2), 1106.
[71]
Lo, P-C. The unique features and promises of phthalocyanines as advanced photosensitisers for photodynamic therapy of cancer. Chem. Soc. Rev., 2020, 49(4), 1041-1056.
[72]
De Groof, T.W.M. Nanobody-Targeted Photodynamic Therapy Selectively Kills Viral GPCR-Expressing Glioblastoma Cells. Mol. Pharm., 2019, 16(7), 3145-3156.
[73]
Lourenço, L.M. Thioglycerol-porphyrin,-chlorin, and-phthalocyanine derivatives for photodynamic therapy of UM-UC-3 bladder cancer cells. J. Photochem. Photobiol. Chem., 2023, 442, 114768.
[74]
Chen, D. Photocyanine: A novel and effective phthalocyanine-based photosensitizer for cancer treatment. J. Innov. Opt. Health Sci., 2020, 13(03), 2030009.
[75]
Norman, D.J. A Dual Killing Strategy: Photocatalytic Generation of Singlet Oxygen with Concomitant PtIV Prodrug Activation. Angew. Chem. Int. Ed., 2019, 58(40), 14189-14192.
[76]
Mazzei, L.F. Toward supramolecular nanozymes for the photocatalytic activation of Pt (iv) anticancer prodrugs. Chem. Commun., 2020, 56(72), 10461-10464.
[77]
Alonso-de Castro, S. Bioorthogonal catalytic activation of platinum and ruthenium anticancer complexes by FAD and flavoproteins. Angew. Chem., 2018, 130(12), 3197-3201.
[78]
Deng, Z.; Li, C.; Chen, S.; Zhou, Q.; Xu, Z.; Wang, Z.; Yao, H.; Hirao, H.; Zhu, G. An intramolecular photoswitch can significantly promote photoactivation of Pt(iv) prodrugs. Chem. Sci., 2021, 12(19), 6536-6542.
[79]
Wang, Z. Phorbiplatin, a highly potent Pt (IV) antitumor prodrug that can be controllably activated by red light. Chem, 2019, 5(12), 3151-3165.
[80]
Stamati, I. Novel photosensitisers derived from pyropheophorbide-a: uptake by cells and photodynamic efficiency in vitro. Photochem. Photobiol. Sci., 2010, 9(7), 1033-1041.
[81]
Duan, X. Photodynamic therapy mediated by nontoxic core–shell nanoparticles synergizes with immune checkpoint blockade to elicit antitumor immunity and antimetastatic effect on breast cancer. J. Am. Chem. Soc., 2016, 138(51), 16686-16695.
[82]
He, C. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. Nat. Commun., 2016, 7(1), 12499.
[83]
Xu, J. Selective photoactivation: From a single unit monomer insertion reaction to controlled polymer architectures. J. Am. Chem. Soc., 2016, 138(9), 3094-3106.
[84]
Yao, H. BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity. Inorg. Chem., 2020, 59(16), 11823-11833.
[85]
Spikes, J.D. New trends in photobiology: Chlorins as photosensitizers in biology and medicine. J. Photochem. Photobiol. B, 1990, 6(3), 259-274.
[86]
Goląb, J. Potentiation of the anti-tumour effects of Photofrin®-based photodynamic therapy by localized treatment with G-CSF. Br. J. Cancer, 2000, 82(8), 1485-1491.
[87]
Overholt, B.F. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett’s esophagus: international, partially blinded, randomized phase III trial. Gastrointest. Endosc., 2005, 62(4), 488-498.
[88]
Dougherty, T.J.; Cooper, M.T.; Mang, T.S. Cutaneous phototoxic occurrences in patients receiving Photofrin®. Lasers Surg. Med., 1990, 10(5), 485-488.
[89]
Xiao, Z. Whole bladder photodynamic therapy for orthotopic superficial bladder cancer in rats: a study of intravenous and intravesical administration of photosensitizers. J. Urol., 2003, 169(1), 352-356.
[90]
Lim, W.Q. Self-Assembled Oxaliplatin(IV) Prodrug–Porphyrin Conjugate for Combinational Photodynamic Therapy and Chemotherapy. ACS Appl. Mater. Interfaces, 2019, 11(18), 16391-16401.
[91]
Su, R. Self-assembling porphyrin conjugate-carboplatin(IV) prodrug nanoparticles for enhancing high efficacy nasopharyngeal cancer and low systemic toxicity. J. Biomater. Sci. Polym. Ed., 2022, 33(14), 1828-1844.
[92]
Hu, X.; Li, R.; Wu, W.; Fang, K.; Zhu, Z.; Wang, Y.; Zhou, L.; Chen, M.; Dong, C.; Shi, S. A Fe(III)-porphyrin-oxaliplatin(IV) nanoplatform for enhanced ferroptosis and combined therapy. J. Cont. Rel., 2022, 348, 660-671.
[93]
Song, H. Light triggered release of a triple action porphyrin-cisplatin conjugate evokes stronger immunogenic cell death for chemotherapy, photodynamic therapy and cancer immunotherapy. J. Nanobiotechnology, 2022, 20(1), 329.
[95]
Khan, M.M.; Adil, S.F.; Al-Mayouf, A. Metal oxides as photocatalysts. J. Saudi Chem. Soc., 2015, 19(5), 462-464.
[96]
Karges, J. Clinical development of metal complexes as photosensitizers for photodynamic therapy of cancer. Angew. Chem. Int. Ed., 2022, 61(5), e202112236.
[97]
Karges, J.; Yempala, T.; Tharaud, M.; Gibson, D.; Gasser, G. A Multi-action and multi-target Ru II -Pt IV conjugate combining cancer-activated chemotherapy and photodynamic therapy to overcome drug resistant cancers. Angew. Chem. Int. Ed. Engl., 2020, 59(18), 7069-7075.
[98]
Scoditti, S. Computational Exploration of the Synergistic Anticancer Effect of a Multi-Action Ru(II)–Pt(IV) Conjugate. Inorg. Chem., 2022, 61(32), 12903-12912.
[99]
Yang, Y. Photodynamic Therapy with Liposomes Encapsulating Photosensitizers with Aggregation-Induced Emission. Nano Lett., 2019, 19(3), 1821-1826.
[100]
Yao, C. Near-infrared-triggered azobenzene-liposome/upconversion nanoparticle hybrid vesicles for remotely controlled drug delivery to overcome cancer multidrug resistance. Adv. Mater., 2016, 28(42), 9341-9348.
[101]
Rwei, A.Y. Repeatable and adjustable on-demand sciatic nerve block with phototriggerable liposomes. Proc. Natl. Acad. Sci. USA, 2015, 112(51), 15719-15724.
[102]
Yang, Y. Light-activatable liposomes for repetitive on-demand drug release and immunopotentiation in hypoxic tumor therapy. Biomaterials, 2021, 265, 120456.
[103]
Zhang, Q. Pt(IV) prodrug initiated microparticles from microfluidics for tumor chemo-, photothermal and photodynamic combination therapy. Bioact. Mater., 2023, 24, 185-196.
[104]
Zhang, Q.; Wang, X.; Kuang, G.; Yu, Y.; Zhao, Y. Photopolymerized 3D printing scaffolds with Pt (IV) prodrug initiator for postsurgical tumor treatment. Research (Wash D C), 2022, 9784510.
[105]
Yang, Y.; Mu, J.; Xing, B. Photoactivated drug delivery and bioimaging. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2017, 9(2), , e1408.
[106]
Alonso-de Castro, S. Catalysis concepts in medicinal inorganic chemistry. Chemistry, 2019, 25(27), 6651-6660.
[107]
Szaciłowski, K. Bioinorganic photochemistry: frontiers and mechanisms. Chem. Rev., 2005, 105(6), 2647-2694.
[108]
Bednarski, P.J.; Mackay, F.S.; Sadler, P.J. Photoactivatable platinum complexes. ANTI-CANCER AGENT ME, 2007, 7(1), 75-93.
[109]
Scoditti, S. Flavin-mediated photoactivation of Pt (iv) anticancer complexes: computational insights on the catalytic mechanism. Phys. Chem. Chem. Phys., 2022, 24(9), 5323-5329.
[110]
Tan, P. Artificial intelligence aids in development of nanomedicines for cancer management. Seminars in Cancer Biology., 2023, 89, 61-75.
[111]
Jordan, M.I. Artificial intelligence—the revolution hasn’t happened yet. Harv. Data Sci. Rev., 2019, 1(1), 1-9.
[112]
Lavecchia, A. Deep learning in drug discovery: opportunities, challenges and future prospects. Drug Discov. Today, 2019, 24(10), 2017-2032.
[113]
Beirne, D.F.; Farkaš, B.; Donati, C. Novel design of dual-action Pt (IV) anticancer pro-drugs based on cisplatin and derivatives of the tyrosine kinase inhibitors imatinib and nilotinib. Dalton Trans., 2023, 52(39), 14110-14122.
Related Books
.jpeg)
1st Biotechnology World Congress - 2012
Decolorization by Thanatephorus Cucumeris Dec 1
Industrial Applications of Soil Microbes
The Future of Agriculture: IoT, AI and Blockchain Technology for Sustainable Farming
Handbook of Integrated Weed Management for Major Field Crops
Practical Biochemistry
Anticancer Drugs Sourced from Marine Life
Opportunities for Biotechnology Research and Entrepreneurship
Diseases of Ornamental, Aromatic and Medicinal Plants
Diabetes and Breast Cancer: An Analysis of Signaling Pathways
